Date: \_\_\_\_\_ 2021.11.28

Your Name: <u>Hao Zhang</u>

Manuscript Title: <u>Downregulation of REV-ERBα is associated with the progression of lung adenocarcinoma</u> Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	Scientific Research Project of Tianjin Chest Hospital (2018XKZ26) the project of Tianjin Science and Technology Innovation
	medical writing, article processing charges, etc.)		Bureau (20JCYBJC01350) the Project of Tianjin Health Commission (ZD20023)
	No time limit for this item.		the Project of Tianjin key Clinical Subject
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
	<b>U</b> ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by grants from Scientific Research Project of Tianjin Chest Hospital (2018XKZ26), the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350) and the Project of Tianjin Health Commission (ZD20023); the Project of Tianjin key Clinical Subject.

### Please place an "X" next to the following statement to indicate your agreement:

Date: \_\_\_\_\_ 2021.11.27

Your Name: <u>Ruichen Shu</u>

Manuscript Title:<u>Downregulation of REV-ERBα is associated with the progression of lung adenocarcinoma</u> Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	-	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	Scientific Research Project of Tianjin Chest Hospital (2018XKZ26)
	provision of study materials, medical writing, article		the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350)
	processing charges, etc.)		the Project of Tianjin Health Commission (ZD20023)
	No time limit for this item.		the Project of Tianjin key Clinical Subject
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
	<b>U</b> ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by grants from Scientific Research Project of Tianjin Chest Hospital (2018XKZ26), the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350) and the Project of Tianjin Health Commission (ZD20023); the Project of Tianjin key Clinical Subject.

### Please place an "X" next to the following statement to indicate your agreement:

Date: \_\_\_\_\_ 2021.11.27

Your Name: <u>Xiaofeng Liu</u>

Manuscript Title:<u>Downregulation of REV-ERBα is associated with the progression of lung adenocarcinoma</u> Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	-	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	Scientific Research Project of Tianjin Chest Hospital (2018XKZ26)
	provision of study materials, medical writing, article		the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350)
	processing charges, etc.)		the Project of Tianjin Health Commission (ZD20023)
	No time limit for this item.		the Project of Tianjin key Clinical Subject
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
	<b>U</b> ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by grants from Scientific Research Project of Tianjin Chest Hospital (2018XKZ26), the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350) and the Project of Tianjin Health Commission (ZD20023); the Project of Tianjin key Clinical Subject.

### Please place an "X" next to the following statement to indicate your agreement:

Date: \_\_\_\_\_ 2021.11.28

Your Name: <u>Xun Zhang</u>

Manuscript Title: <u>Downregulation of REV-ERBα is associated with the progression of lung adenocarcinoma</u> Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	Scientific Research Project of Tianjin Chest Hospital (2018XKZ26) the project of Tianjin Science and Technology Innovation
	medical writing, article processing charges, etc.)		Bureau (20JCYBJC01350) the Project of Tianjin Health Commission (ZD20023)
	No time limit for this item.		the Project of Tianjin key Clinical Subject
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
	<b>U</b> ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by grants from Scientific Research Project of Tianjin Chest Hospital (2018XKZ26), the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350) and the Project of Tianjin Health Commission (ZD20023); the Project of Tianjin key Clinical Subject.

### Please place an "X" next to the following statement to indicate your agreement:

Date: \_\_\_\_\_ 2021.11.28

Your Name: <u>Daqiang Sun</u>

Manuscript Title:<u>Downregulation of REV-ERBα is associated with the progression of lung adenocarcinoma</u> Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	Scientific Research Project of Tianjin Chest Hospital (2018XKZ26) the project of Tianjin Science and Technology Innovation
	medical writing, article		Bureau (20JCYBJC01350)
	processing charges, etc.)		the Project of Tianjin Health Commission (ZD20023)
	No time limit for this item.		the Project of Tianjin key Clinical Subject
_	-	Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V N	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
	<b>U</b> ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author reports that this work was supported by grants from Scientific Research Project of Tianjin Chest Hospital (2018XKZ26), the project of Tianjin Science and Technology Innovation Bureau (20JCYBJC01350) and the Project of Tianjin Health Commission (ZD20023); the Project of Tianjin key Clinical Subject.

## Please place an "X" next to the following statement to indicate your agreement: